In an interview on CNBC’s Mad Money, Geoff Martha said Medtronic (MDT) has made a strong move into robotics. The company is innovating and creating a “new standard of care,” he added. Martha called Medtronic’s recent partnership with Abbott Labs (ABT) a “win win” for both companies. He said GLP-1 drugs have not had a major impact on the company. The adoption of AI in healthcare is a growing trend and one Medtronic plans to take advantage of, he noted.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDT:
- Needham medtech & diagnostics analyst holds analyst/industry conference call
- Election 2024: Where To Put Your Money Ahead of the Vote
- Medtronic price target raised to $90 from $85 at Truist
- Medtronic price target raised to $105 from $104 at Barclays
- Street analysts say diabetes stocks âoverreactingâ to Lilly GLP-1 study results
Questions or Comments about the article? Write to editor@tipranks.com